Vor Biopharma Inc. VOR

VOR Company Overview

Vor Biopharma Inc. is a U.S.-based clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies and targeted immunotherapies for blood cancers. The company operates within the biotechnology and oncology sectors, with a primary emphasis on acute myeloid leukemia (AML) and related hematologic malignancies. Vor’s core strategy centers on genetically modifying healthy stem cells to remove specific target antigens, enabling subsequent cancer therapies to attack malignant cells while reducing damage to normal blood-forming cells.

The company’s principal programs have included engineered stem cell platforms such as trem-cel and associated targeted therapies including VCAR33 and monoclonal antibody approaches directed at CD33-positive leukemias. Vor Biopharma was founded in 2015 and is headquartered in Cambridge, Massachusetts. The company became publicly traded on the Nasdaq under the ticker VOR following its initial public offering in 2021. Its positioning within the oncology market is based on combining cell engineering with precision immunotherapy to potentially expand the therapeutic window for AML treatment.